Last reviewed · How we verify
Novoseven
At a glance
| Generic name | Novoseven |
|---|---|
| Also known as | recombinant activated factor VII |
| Sponsor | AryoGen Pharmed Co. |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India (PHASE4)
- An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
- SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis (PHASE3)
- A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia (PHASE3)
- Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2 (PHASE3)
- Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial (PHASE3)
- SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors (PHASE4)
- Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |